TP53 and neoplasm: Despite the many studies, however, the results have been inconsistent, with some studies reporting an association between p53 expression and tumor response to neoadjuvant anthracyclines [27-29], whereas other reports have associated p53 overexpression with both resistance [30,31] and sensitivity [32,33] to preoperative anthracycline-containing chemotherapy.